A waterfall plot was constructed to show maximum changes in tumor size of patients receiving HAIC combined lenvatinib and PD-1 antibody (Figure 2) and favorable tumor response of patient with large hepatocellular carcinoma or main portal vein tumor thrombus hepatocellular carcinoma treated by HAIC combined lenvatinib and PD-1 antibody (Figure 3). Here, PDCD1 is linked to hepatocellular carcinoma.